Pedro Perez: Are We Measuring the Right Outcomes in VTE?
Pedro Perez, Senior Vascular Consultant at Argon Medical Devices, Inc., shared a post on LinkedIn:
”Are We Measuring the Right Outcomes in VTE?
In VTE, we often talk about technical success:
- Did we remove the clot?
- Did flow improve?
- Did the case go smoothly?
But the bigger question is… does that actually define success for the patient?
Because what matters long-term isn’t just what happens in the lab – it’s what happens after:
- Reduction in post-thrombotic syndrome
- Improvement in quality of life
- Decreased readmissions
- Shorter hospital stays and overall cost of care
As technology continues to evolve – from aspiration to more advanced thrombectomy approaches – we’re getting better at treating clot.
But as an industry, we need to continue shifting the conversation from procedural metrics to patient outcomes.
The next phase of VTE care won’t be defined by who has the newest device…
It will be defined by who can demonstrate meaningful, measurable impact on patients.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 08:46Ruben Mesa: Exploring New Treatment Options for Myelofibrosis-Related Anemia at EHA 2026
-
Jun 14, 2026, 08:32Manuela Spadea: Celebrating Recognition for Pediatric HSCT Research at EHA 2026
-
Jun 14, 2026, 08:17Amber Yates: Honoring the Sickle Cell Community Behind the Rise Up Study
-
Jun 14, 2026, 06:19Sharmila Manian: World Blood Donor Day – Where Generosity Meets Smart Medicine
-
Jun 14, 2026, 06:04Vishnu R.: FedServ Employees Unite to Save Lives Through Blood Donation
-
Jun 13, 2026, 20:28Tarun Tyagi: Translational Insights into Severe Immune Thrombocytopenia
-
Jun 13, 2026, 18:25Miguel Gómez Álvarez: Reviewing Inflammation, Transplantation, and Gene Therapy in Hemoglobinopathies
-
Jun 13, 2026, 18:24Ana Pedrero Gil: Why Factor XIII Deficiency Is Often Overlooked During Acute Bleeding
-
Jun 13, 2026, 18:23Tobias Degsell: Building Stronger Bridges Across Disciplines, Countries, and Perspectives at EHA 2026